Parnaparin sodium oral

Drug Profile

Parnaparin sodium oral

Alternative Names: CB-01-05; CB-01-05-MMX™; Extended-release parnaparin sodium; LMW Heparin MMX; Low molecular weight heparin oral - Cosmo Pharmaceuticals

Latest Information Update: 15 Jun 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cosmo Pharmaceuticals
  • Class Anticoagulants; Low molecular weight heparins; Vascular disorder therapies
  • Mechanism of Action Cytokine inhibitors; Interleukin 2 inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Ulcerative colitis

Most Recent Events

  • 15 Jun 2015 Parnaparin sodium oral is still in phase II development for Ulcerative colitis in UK
  • 18 Feb 2014 Parnaparin sodium oral is still in phase II development for Ulcerative colitis in UK
  • 21 Apr 2008 Preliminary efficacy and adverse events data from a Phase-IIb trial in Ulcerative colitis released by Cosmo Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top